Aviptadil, 66 microgram/mL ( DrugBank: Aviptadil )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-002174-22-DE (EUCTR) | 08/11/2006 | 23/08/2006 | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Pulmonary Fibrosis categorized as UIP or NSIP | Product Name: Aviptadil, 66 microgram/mL Other descriptive name: Vasoactive intestinal peptide | Mondobiotech Laboratories Anstalt | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Germany |